{"created":"2023-07-27T06:50:43.595536+00:00","id":43752,"links":{},"metadata":{"_buckets":{"deposit":"95fe4257-ee54-41d0-9023-03ad9488fe6b"},"_deposit":{"created_by":18,"id":"43752","owners":[18],"pid":{"revision_id":0,"type":"depid","value":"43752"},"status":"published"},"_oai":{"id":"oai:kanazawa-u.repo.nii.ac.jp:00043752","sets":["2812:2813:2822"]},"author_link":["69424","47737"],"item_9_biblio_info_8":{"attribute_name":"書誌情報","attribute_value_mlt":[{"bibliographicIssueDates":{"bibliographicIssueDate":"2012-04-26","bibliographicIssueDateType":"Issued"},"bibliographicPageStart":"6p.","bibliographicVolumeNumber":"2009-2011","bibliographic_titles":[{"bibliographic_title":"平成23(2011)年度 科学研究費補助金 基盤研究(B) 研究成果報告書"},{"bibliographic_title":"2011 Fiscal Year Final Research Report","bibliographic_titleLang":"en"}]}]},"item_9_creator_33":{"attribute_name":"著者別表示","attribute_type":"creator","attribute_value_mlt":[{"creatorNames":[{}],"nameIdentifiers":[{},{}]}]},"item_9_description_21":{"attribute_name":"抄録","attribute_value_mlt":[{"subitem_description":"HGFによるEGFR-TKI耐性に対する新規肺癌治療法を開発し、HGFによる耐性を予測するバイオマーカーを確立することを目的に研究を行った。EGFR変異を有する肺癌細胞株を用いた検討より、HGF-Met阻害薬はHGFによるEGFR-TKI耐性をin vitroのみならずin vivoにおいても克服することを明らかにした。また、日本人EGFR変異肺癌症例から得た臨床検体を用いた検討において、HGFは、EGFR-TKIの獲得耐性のみならず自然耐性をも誘導し、少なくとも今回の日本人EGFR変異肺がん症例においては最も頻度の高い耐性因子であることを示した。さらに、治療前の血漿中HGFがEGFR-TKI治療の効果予測バイオマーカーになる可能性を示した。以上の成果から、HGFはEGFR-TKIを用いた肺癌の個別化医療において重要な標的およびバイオマーカーであることが明らかとなった。","subitem_description_type":"Abstract"},{"subitem_description":"The purpose of this study was to develop novel therapy for overcoming HGF-induced EGFR-TKI resistance and establish biomarkers which predict the HGF-induced resistance in lung cancer. We found that inhibitors of HGF-Met could overcome HGF-induced EGFR-TKI resistance in EGFR mutant lung cancer cells in vitro and in vivo. Our study with clinical specimens reveled that high levels of HGF were detected in tumors with acquired and intrinsic resistance to EGFR-TKI and was the most prevalent factor for resistance, at least in Japanese patients with EGFR-mutant lung cancer. We further demonstrated that levels of HGF in plasma before EGFR-TKI treatment inversely correlated with clinical response in lung cancer. These finding suggest that HGF is the important target and biomarker of individual therapy with EGFR-TKI in lung cancer.","subitem_description_type":"Abstract"}]},"item_9_description_22":{"attribute_name":"内容記述","attribute_value_mlt":[{"subitem_description":"研究課題/領域番号:21390256, 研究期間(年度):2009-2011","subitem_description_type":"Other"},{"subitem_description":"出典：研究課題「HGFによるEGFR活性型変異陽性肺癌の分子標的薬耐性を克服する個別化医療開発」課題番号21390256\n（KAKEN：科学研究費助成事業データベース（国立情報学研究所）） \n（https://kaken.nii.ac.jp/report/KAKENHI-PROJECT-21390256/21390256seika/）を加工して作成","subitem_description_type":"Other"}]},"item_9_identifier_registration":{"attribute_name":"ID登録","attribute_value_mlt":[{"subitem_identifier_reg_text":"10.24517/00050094","subitem_identifier_reg_type":"JaLC"}]},"item_9_publisher_17":{"attribute_name":"公開者","attribute_value_mlt":[{"subitem_publisher":"金沢大学がん進展制御研究所"}]},"item_9_relation_28":{"attribute_name":"関連URI","attribute_value_mlt":[{"subitem_relation_name":[{"subitem_relation_name_text":"https://kaken.nii.ac.jp/search/?qm=30294672"}],"subitem_relation_type_id":{"subitem_relation_type_id_text":"https://kaken.nii.ac.jp/search/?qm=30294672","subitem_relation_type_select":"URI"}},{"subitem_relation_name":[{"subitem_relation_name_text":"https://kaken.nii.ac.jp/grant/KAKENHI-PROJECT-21390256/"}],"subitem_relation_type_id":{"subitem_relation_type_id_text":"https://kaken.nii.ac.jp/grant/KAKENHI-PROJECT-21390256/","subitem_relation_type_select":"URI"}},{"subitem_relation_name":[{"subitem_relation_name_text":"https://kaken.nii.ac.jp/report/KAKENHI-PROJECT-21390256/21390256seika/"}],"subitem_relation_type_id":{"subitem_relation_type_id_text":"https://kaken.nii.ac.jp/report/KAKENHI-PROJECT-21390256/21390256seika/","subitem_relation_type_select":"URI"}}]},"item_9_version_type_25":{"attribute_name":"著者版フラグ","attribute_value_mlt":[{"subitem_version_resource":"http://purl.org/coar/version/c_ab4af688f83e57aa","subitem_version_type":"AM"}]},"item_files":{"attribute_name":"ファイル情報","attribute_type":"file","attribute_value_mlt":[{"accessrole":"open_date","date":[{"dateType":"Available","dateValue":"2018-02-09"}],"displaytype":"detail","filename":"CA-PR-YANO-S-kaken 2012-6p.pdf","filesize":[{"value":"543.9 kB"}],"format":"application/pdf","licensetype":"license_11","mimetype":"application/pdf","url":{"label":"CA-PR-YANO-S-kaken 2012-6p.pdf","url":"https://kanazawa-u.repo.nii.ac.jp/record/43752/files/CA-PR-YANO-S-kaken 2012-6p.pdf"},"version_id":"3fcaa6e5-5aa5-4d90-87a0-58dc7c84ab0d"}]},"item_language":{"attribute_name":"言語","attribute_value_mlt":[{"subitem_language":"jpn"}]},"item_resource_type":{"attribute_name":"資源タイプ","attribute_value_mlt":[{"resourcetype":"research report","resourceuri":"http://purl.org/coar/resource_type/c_18ws"}]},"item_title":"HGFによるEGFR活性型変異陽性肺癌の分子標的薬耐性を克服する個別化医療開発","item_titles":{"attribute_name":"タイトル","attribute_value_mlt":[{"subitem_title":"HGFによるEGFR活性型変異陽性肺癌の分子標的薬耐性を克服する個別化医療開発"},{"subitem_title":"Development of individual therapy for overcoming HGF-induced molecular targeted drug-resistance in EGFR-mutant lung cancer","subitem_title_language":"en"}]},"item_type_id":"9","owner":"18","path":["2822"],"pubdate":{"attribute_name":"公開日","attribute_value":"2018-02-09"},"publish_date":"2018-02-09","publish_status":"0","recid":"43752","relation_version_is_last":true,"title":["HGFによるEGFR活性型変異陽性肺癌の分子標的薬耐性を克服する個別化医療開発"],"weko_creator_id":"18","weko_shared_id":-1},"updated":"2023-07-27T13:28:37.347367+00:00"}